Gossamer Bio Completes $72M Convertible Note Exchange
Gossamer Bio announced the final tender results of its previously announced exchange offer to exchange any and all of its 5.00% Convertible Senior Notes due 2027 for a pro rata portion of up to $72M in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes due 2030, up to 317,647,058 shares of its common stock or, in lieu of issuing shares of Common Stock to the extent such shares would cause any holders of Existing Convertible Notes that are "qualified institutional buyers" as defined in Rule 144A under the Securities Act to beneficially own greater than 9.99% of the outstanding Common Stock, prefunded warrants to purchase shares of Common Stock and with respect to Eligible Holders who tender prior to the Extended Early Tender Date, warrants to purchase shares of Common Stock. As previously announced, as of 5:00 p.m., New York City time, on June 2, $181,052,000 in aggregate principal amount of Existing Convertible Notes was validly tendered in the Exchange Offer and not validly withdrawn and related consents to the Proposed Amendments were validly delivered and not validly withdrawn as of such time, and the Company and the Required Supporting Noteholders agreed to amend the condition to the Exchange Offer that a minimum of 98% of the aggregate principal amount of Existing Convertible Notes be validly tendered to a minimum of 90.5% of the aggregate principal amount of Existing Convertible Notes be validly tendered. As a result, early settlement of Offered Securities in exchange for the Early Tendered Notes validly tendered and not validly withdrawn as of the Extended Early Tender Date occurred on June 4, 2026, and the Company entered into a supplemental indenture eliminating substantially all of the restrictive covenants in the indenture governing the Existing Convertible Notes, as well as certain events of default and related provisions applicable to the Existing Convertible Notes. As of 5:00 p.m., New York City time, on June 16, 2026, based on information provided by D.F. King & Co., Inc., which is acting as the exchange agent and information agent for the Exchange Offer, no additional Existing Convertible Notes were validly tendered in the Exchange Offer. As a result, $18,948,000 in aggregate principal amount of the Existing Convertible Notes will remain outstanding following this Exchange Offer.
Trade with 70% Backtested Accuracy
Analyst Views on GOSS
About GOSS
About the author

- New Scientific Advisor: Harbour BioMed has appointed Dr. Luisa Salter-Cid as Scientific Advisor, bringing over 20 years of leadership experience in biotech and pharmaceuticals, which is expected to enrich the company's expertise and strategic direction.
- Clinical Development Achievements: During her tenure at Bristol Myers Squibb, Salter-Cid successfully advanced over 20 compounds into clinical development, showcasing her exceptional ability to translate discoveries into clinical applications, which will help accelerate Harbour BioMed's antibody therapeutic pipeline.
- Technological Platform Advantage: Harbour BioMed's Harbour Mice® technology platform generates fully human monoclonal antibodies, and combined with HCAb technology, it offers tumor-killing effects that traditional combination therapies cannot achieve, with Salter-Cid's expertise likely enhancing its application potential.
- Global Medical Needs: Salter-Cid's strategic insights will assist Harbour BioMed in addressing unmet medical needs globally, driving the company's efforts in innovative drug development, thereby enhancing its market competitiveness and industry standing.
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, seeking damages for investors who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal risks that could impact the company's stock performance.
- Allegations of False Statements: The complaint alleges that Gossamer Bio concealed critical adverse facts regarding inadequate placebo control at Latin American testing sites while promoting positive results from its Phase 3 PROSERA study, leading investors to purchase shares at artificially inflated prices, potentially triggering a market trust crisis.
- Investor Rights Protection: Investors are encouraged to apply to be lead plaintiffs by June 1, 2026, indicating that the legal process provides an opportunity for affected investors to recover losses, which may influence the company's future capital structure and investor confidence.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions for investors, showcasing its expertise in securities fraud cases, which may attract more investors to participate in the lawsuit.
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action for failing to disclose that Latin American patients performed well on placebo, leading to the Phase 3 PROSERA study not meeting its primary endpoint, with shareholders encouraged to participate before the deadline.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is accused of overstating progress on its Texas Critical Data Centers project and engaging in fraudulent schemes, prompting shareholders to act before the deadline.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is under scrutiny for misleading statements regarding its projected book-to-bill ratio for Q4 2025, with investors advised to participate in the lawsuit before the deadline.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses during the relevant periods to contact them to understand their legal rights and steps to participate in the class actions.
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting a severe loss of investor confidence in the company's future prospects, which may jeopardize its listing status on Nasdaq.
- Investor Losses: Hagens Berman law firm is urging investors who suffered substantial losses during the class period to submit claims, suggesting that this event could trigger a wave of investor claims, further impacting the company's financial health.
- Regulatory Scrutiny: The lawsuit alleges improper disclosures regarding trial design and patient recruitment, which may subject Gossamer to stricter regulatory scrutiny, affecting its future financing and market credibility.
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026.
- False Statements Allegation: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could adversely affect its future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to take action before the class action is certified to ensure their rights are protected and to avoid being an absent class member.
- Lawsuit Background: Gossamer Bio, Inc. is facing a class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock plummeted by 80%, reflecting investor disappointment in the company's future prospects and prompting Hagens Berman to investigate possible violations of federal securities laws, which could lead to further legal liabilities.
- Trial Design Issues: The lawsuit alleges that Gossamer misrepresented the PROSERA trial design, including patient recruitment and monitoring, as management previously claimed the drug had the potential to be a “first-in-class therapeutic,” but the actual results failed to support this assertion, potentially undermining investor confidence.
- Nasdaq Compliance Risks: On April 9, 2026, Gossamer revealed that it had not met the minimum bid price requirement ($1) for continued listing on the Nasdaq Global Select Market since February 24, 2026, exacerbating investor concerns about the company's future and potentially impacting its ability to raise capital and maintain market position.











